VIGOR: Virtual Genome Center for Infant Health

Part of paid clinical trials in Mobile, Alabama.

Sponsor
Boston Children's Hospital
Study ID
NCT05205356
Status
Recruiting

Conditions

  • Genetic Predisposition to Disease
  • Genetics Disease
  • Genetics/Birth Defects

Eligibility Criteria

Sex
ALL
Age
0 Days - 99 Years
Healthy Volunteers
Not accepted

Study Details

This study will provide rigorous evaluation of implementing a virtual genome center into community clinical settings without highly specialized resources, thereby offering generalizable insights as to how best to implement genomic medicine at scale and for other age groups. This intervention has great potential to address disparities in genomic medicine among low-income and underrepresented minority (URM) populations and will enhance capacity for providers and health systems to utilize highly specialized genomic techniques in their communities. The goal of this study is to achieve equitable access to state-of-the-art genomic medical care to sick newborns in community centers that predominately care for low-income and racial/ethnic minority populations through the creation of a virtual genome center (VIGOR). VIGOR will provide a venue for physician and family education, genomic expert consultation, reanalysis of unsolved sequencing data, and access to cutting edge therapeutic innovation, thereby facilitating institutionalization of genomic best practices in community settings, and not just highly specialized referral centers.

Key Dates

Start date
Mar 22, 2022
Status verified
Jan 2026
Primary completion
Nov 30, 2026
Completion
Mar 1, 2027

Study Design

Enrollment
750 participants (estimated)

Arms

  • Arm: Neonates and Parents/Caregivers
    Providers caring for newborns that meet eligibility criteria will approach parents to assess interest. The VIGOR study staff will remotely contact parents to complete consent for genomic sequencing (GS). We will also invite 1 additional primary caregiver (e.g. father, co-mother etc.) to participate even if that caregiver is not biologically related to the child. We will administer surveys at baseline enrollment to assess sociodemographics, obstetrical history, family genetic history \& mental health; within 1 week of disclosure of findings to assess satisfaction \& mental health; \& at 3 \& 6 months to further assess mental health \& newborn clinical outcomes. We will approach a subset of the families for qualitative interviews to assess satisfaction with VIGOR \& receipt of GS results with their physician in more detail.
  • Arm: Clinicians
    Following focus groups at each of the participating sites to assess the feasibility \& needs of each site, the care teams will receive basic training in genomics and how to disclose GS results with VIGOR support. Study orientation will be completed as part of the training. Focus groups will be conducted within 1 year post implementation \& again between year 4 \& the completion of the study, to assess feasibility \& appropriateness of VIGOR. We will administer brief surveys to the care providers before \& after receipt of genomic education to assess their baseline knowledge \& comfort with genomic medicine in newborns. Surveys will be repeated within a week of disclosure to families regarding feedback on the process \& satisfaction with VIGOR. After approximately 3-5 disclosure events, study staff will approach the clinical care team members to participate in a qualitative interview to assess their perspectives in more depth.

Primary Outcome Measure

Implementation of VIGOR [ Time Frame: 4 year ]

Central Contacts

Locations (10)

FacilityCityStateZIPSite coordinators
USA Children's and Women's HospitalMobileAlabama36604
Ellen Dean, BSN, RN
251-415-1088
Manimaran Ramani, MD (PRINCIPAL_INVESTIGATOR)
Holtz Children's Hospital at Jackson Memorial Medical CenterMiamiFlorida33136
Pankaj Agrawal, MD, MMSC
617-919-2357
Pankaj Agrawal, MD, MMSC (PRINCIPAL_INVESTIGATOR)
Boston Medical CenterBostonMassachusetts02118
Bharati Sinha, MD
Bharati Sinha, MD (PRINCIPAL_INVESTIGATOR)
Baystate Medical CenterSpringfieldMassachusetts01199
Robert Rothstein
413-794-2400
Robert Rothstein, MD (PRINCIPAL_INVESTIGATOR)
UMass Memorial HospitalWorcesterMassachusetts01605
Lawrence Rhein, MD, MPH
508-334-6206
Anjana Bhami Shenoy
508-334-6090
Lawrence Rhein, MD, MPH (PRINCIPAL_INVESTIGATOR)
Cooper University HospitalCamdenNew Jersey08103
Vineet Bhandari, MD, DM
856-342-2000
Faye Shapiro, MS, LCGC
856-541-6213
Vineet Bhandari, MD, DM (PRINCIPAL_INVESTIGATOR)
Driscoll Children's Hospital Rio Grande ValleyEdinburgTexas78539
Dynio Honrubia, MD
956-802-8855
The Women's Hospital at RenaissanceEdinburgTexas78539
Dynio Honrubia, MD
956-802-8855
Dynio Honrubia, MD (PRINCIPAL_INVESTIGATOR)
The Hospitals of ProvidenceEl PasoTexas79938
Dhruv Gupta, MD
313-896-8168
Jenifer Gehlsen, MD
Dhruv Gupta, MD (PRINCIPAL_INVESTIGATOR)
University of Texas Medical BranchGalvestonTexas77555
Maria E Franco-Fuenmayor, MD
409-772-2815
Maria E Franco-Fuenmayor, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Mobile, AL

Related Studies